Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE) (2020) Talhouk A, George J, Wang C, Budden T, Tan TZ, Chiu DS, Kommoss S, et al. Journal article Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α (2020) Ingle JN, Cairns J, Suman VJ, Shepherd LE, Fasching P, Hoskin TL, Singh RJ, et al. Journal article A small hypoxia signature predicted pCR response to bevacizumab in the neoadjuvant GeparQuinto breast cancer trial (2020) Karn T, Meissner T, Weber KE, Solbach C, Denkert C, Engels K, Fasching P, et al. Journal article Tumor growth rate as a validated early radiological biomarker able to reflect treatment-induced changes in neuroendocrine tumors: The GREPONET-2 study (2019) Lamarca A, Ronot M, Moalla S, Crona J, Opalinska M, Lopez CL, Pezzutti D, et al. Journal article A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO) (2019) Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, et al. Journal article A five-microRNA signature predicts survival and disease control of patients with head and neck cancer negative for HPV infection (2019) Hess J, Unger K, Maihoefer C, Schuettrumpf L, Wintergerst L, Heider T, Weber P, et al. Journal article Mutational diversity and therapy response in breast cancer: A sequencing analysis in the neoadjuvant geparsepto trial (2019) Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, et al. Journal article A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NeO-ORB) (2019) Mayer IA, Prat A, Egle D, Blau S, Alejandro Perez Fidalgo J, Gnant M, Fasching P, et al. Journal article Functional parameters derived from magnetic resonance imaging reflect vascular morphology in preclinical tumors and in human liver metastases (2018) Kannan P, Kretzschmar WW, Winter H, Warren D, Bates R, Allen PD, Syed N, et al. Journal article Identification of CRKII, CFL1, CNTN1, NME2, and TKT as novel and frequent T-cell targets in human IDH-mutant glioma (2018) Dettling S, Stamova S, Warta R, Schnoelzer M, Rapp C, Rathinasamy A, Reuss D, et al. Journal article